China-based drug manufacturer Jilin Zixin Pharmaceutical Co Ltd (Zixin Pharma) is investing up to $42 million in Nabsys 2.0, a high definition whole genome mapping company in the US.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
